DRG International, a leading international medical diagnostic company, will showcase its DRG® Aldosterone ELISA Kit at the 2015 AACC in Atlanta, Georgia on July 27-30. The DRG International Aldosterone ELISA is for measurement of Aldosterone in serum, plasma, and urine.
DRG International’s Renin (Active) ELISA for testing of active Renin in human EDTA plasma will be on display at the AACC’s 2015 show Atlanta, Georgia on July 27-30. The DRG® Renin active ELISA test is accurate in testing for certain types of hypertension and has been utilized by labs world-wide.
Total Lab Care (TLC), an ELITechGroup specialized consultant provider for Physician Office Laboratories (POLs) announces that its Laboratory Essentials Course has been approved for 3.5 hours of P.A.C.E. continuing education credits. Course participants will learn or refresh their memory on the basics of the clinical laboratory in a self‐paced environment. This web‐based interactive training program, comprised of 10 individual lessons, reviews CLIA rules and regulations and laboratory operations from pre‐analytical to post‐analytical processes including laboratory testing requirements (i.e. pipetting, safety, equipment operation, etc.).
EMD Millipore Introduces New High-Performance Water Purification Systems with 24/7 Real-Time Monitoring and Remote Control • New AFS® 40E / 80E / 120E and 150E systems fulfill pure water needs for one or several high-throughput clinical analyzers.
Kathy Holland, MD is the Director of Operations and Medical Director of Equitech Enterprises which supplies custom normal and disease state blood collections. Dr. Holland has extensive experience in the human blood collection field. From being a small enterprise, she has increased its donor base to include a wide range of age, ethnicity, and disease state. All collections receive viral screening including HIV, Hepatitis B&C, Syphilis, and other selected markers. All donors receive, and are qualified by, a fully comprehensive three page Donor Health Questionnaire in which data and demographics information is given on request. They provide custom specimen collections or bulk quantities ranging from a single unit to hundreds of liters. Equitech Enterprises, Inc. is FDA Approved, and IRB Certified.
KNF Neuberger, Inc. announces an extension to the line of brushless DC powered NFB boxer pumps with the addition of two compact, powerful models. The new NFB 5 and NFB 25 feature low pulsation, gentle transfer of liquids from 5 – 300 mL/min per head, and cost savings thanks to efficient design and long product life.
MBS MAB230P, monoclonal antibody to the polyhistidine (HIS) tag has been incorporated into the second generation Forte Bio Anti-HIS biosensors for rapid quantitative measurement of HIS tagged proteins. MAB230P was selected by ForteBio after demonstrating high specificity and excellent sensitivity, detecting HIS tagged proteins in nanogram quantities. The antibody is broadly reactive, recognizing HIS tags of 4X or greater, engineered at either the N- or C-terminus of the protein. The internal development and production of MAB230P allows MBS to maintain the highest quality standards and the ability to offer the lowest price in the marketplace.
Activity and outcome scores like DAS, DAS28, SDAI or CDAI, Larsen Score, etc. are commonly used but are time consuming and not practical in the early phase of rheumatoid arthritis (RA). Moreover, no validated or accepted uniform criteria exist to classify individuals with early RA in terms of disease progression and severity. Even if CCP has been added to the 2010 ACR criteria for diagnostic purposes, its usefulness as a marker for disease activity and progression is still under discussion. But this information is exactly what is needed to choose the appropriate therapy because not all early disease patients are candidates for DMARD or biological therapy, mainly due to toxicity reasons. Aggressive therapy is recommended only for those who are at risk of rapid joint destruction.
Seralite® - FLC is a rapid diagnostic device for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum as an aid to the diagnosis and management of multiple myeloma. The assay provides an accurate picture of disease status in 10 minutes. Using a simple to use, portable, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making
Yantai Addcare Bio-Tech Limited Company is a high-tech enterprise engaged in the development, production and sales of fully automated liquid handling systems, immunoassay workstations and related products. We are currently the only manufacturer in China holding independent intellectual property rights in this product segment.
Background Immunofluorescence Assays (IFA) used for screening of autoimmune diseases have a number of challenges. When performed manually, IFA is laborious, subjective and poorly standardized. With the advent of multiplex technologies in early-2000, the autoimmune community thought it had found a solution, until it became evident that multiplex technologies had limitations, which made them poor candidates for antinuclear antibody screening (ANA). Today, there are 30 to 50 clinically significant autoantibodies outside of the HEp-2 cell, which currently have no method for screening.1
Every baby born that enters this world, arrives with an umbilical cord in tow. For those babies born addicted to drugs, that umbilical cord is now a key connection—a hard to hide clue—for identifying what drugs are coursing through a newborn’s veins. The drug(s) detected will help physicians determine the best treatment and what withdrawal symptoms to expect.
“There is no cure for HHT, yet if we can find new genetic modifiers or new genes, then we can potentially find novel therapeutics to treat these patients,” explains an enthusiastic Whitney Wooderchak-Donahue, PhD, a researcher with the University of Utah and ARUP Laboratories. Last week, she received the 2015 Young Scholar Research Grant ($30,000) for her research proposal that involves focusing on patients’ transcripts (the RNA in the cell) via their blood samples to identify genetic modifiers in Hereditary Hemorrhagic Telangiectasia (HHT).
Asahi Kasei Fibers has begun commercial production and supply of NanoAct™ cellulose nanobeads, and is now accelerating the development of lateral flow immunoassays in Japan and worldwide.
Remember when the doctor came to your house? Well, your grandmother does. Now doctors are coming to the workplace. Not only is it convenient for employees—saving time and keeping them nearby—but, executives are seeing company savings in a time of rising healthcare costs.
As thousands turn out this spring to run and walk in memory of loved ones lost to breast cancer, behind-the-scene researchers are running a race of a different kind to help physicians treat their cancer patients. It is a race to acquire genetic knowledge, and success is dependent on collaborations and expertise from researchers worldwide.
Beckman Coulter Diagnostics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Access 25(OH) Vitamin D Total assay. Offering state-of-the-art performance, the new assay is an important addition to the company’s bone metabolism assay menu and is available for use on its Access 2 and UniCel DxI series of immunoassay systems.
DRG International, a leading international medical diagnostic company, will showcase the NEW DRG® Hepcidin 25 (bioactive) HS (High Sensitive) ELISA Kit (EIA-5782) at the 2015 AACC in Atlanta, Georgia from July 27-30. As the first of its kind to market, this kit accurately detects bioactive Hepcidin levels as an additional marker to aid in identifying a variety of disorders. In recent years, a large number of publications identify Hepcidin as a factor in regulating the amount of iron in humans. Unbalanced iron level can lead to many common medical conditions including anemia and iron overload disease, and can occur in chronic kidney disease, inflammation, or diabetes mellitus
Our main products are: automated immunoassay workstation ( Elisa & Clia series ); automated liquid handlig platform; OEM and custom development series.
Following the commercial launch of Seralite® - FLC Abingdon Health is looking to appoint distributors in order to enable as many people as possible affected by multiple myeloma (a cancer arising from plasma cells) to have access to, and benefit from its rapid diagnostic capabilities.
The Lee Company’s new LPG Series Inert Solenoid Pump was designed to offer greater design flexibility and significant cost savings to the medical and scientific industries.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that it has been honored with a 2015 ASAE Power of A Gold Award for Lab Tests Online.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that the impact factor of its journal, Clinical Chemistry, has increased to 7.9 in the 2014 Thomson Reuters Journal Citation Reports. This increase places Clinical Chemistry in the top 3% of all academic journals and reflects the significant influence of the research it publishes on laboratory medicine and patient care.
The Diatron Group,a global provider of hematology and clinical chemistry analyzers, will display its new economic walk-away clinical chemistry analyzer, the Pictus P500, at the AACC, Atlanta (28-30 July 2015), on booth No 2100.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is seeking applications for editor-in-chief of a new journal: The Journal of Applied Laboratory Medicine: An AACC Publication. Set to launch in 2016, this international, peer-reviewed publication will showcase applied research on clinically relevant laboratory topics as well as commentary on the practice of clinical chemistry and laboratory medicine.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce the upcoming launch of a new journal: The Journal of Applied Laboratory Medicine: An AACC Publication. Set to debut in 2016, this international, peer-reviewed publication will showcase applied research on clinically relevant laboratory topics as well as commentary on the practice of clinical chemistry and laboratory medicine.
Today AACC released a position statement endorsing efforts within the healthcare community to improve patient outcomes by personalizing medical care. The statement emphasizes the central role that innovative laboratory tests play in precision medicine, and stresses the need for policymakers and insurers to adopt policies that ensure access to and appropriate reimbursement for these tests so that patients can benefit from targeted treatments.
Cannabis plus alcohol is one of the most frequently detected drug combinations in car accidents, yet the interaction of these two compounds is still poorly understood. A study appearing online today in Clinical Chemistry, the journal of AACC, shows for the first time that the simultaneous use of alcohol and cannabis produces significantly higher blood concentrations of cannabis’s main psychoactive constituent, Δ9-tetrahydrocannabinol (THC), as well as THC’s primary active metabolite, 11-hydroxy-THC (11-OH-THC), than cannabis use alone.
AACC, a global scientific and medical professional organization dedicated to better health through laboratory medicine, is pleased to announce that it has received three 2015 Hermes Creative Awards. These awards recognize the association for the exceptional writing and design of its news publications and website, which help laboratory medicine professionals worldwide stay informed about important issues in the field and find solutions to challenging patient health problems.
One of the biggest difficulties faced by worldwide programs aimed at eliminating malaria is that the tests they use are not sensitive enough to detect all people who have the disease and need treatment. A study appearing online today in Clinical Chemistry, the journal of AACC, shows that a new test known as capture and ligation probe-PCR (CLIP-PCR) could diagnose the malaria cases that would typically escape detection and lead to new infections.
AACC is pleased to announce that Lauren Kramer was named vice president of education and meetings, effective May 4. Prior to joining AACC, Kramer served as director of meetings at the International Council of Ophthalmology, an organization that represents more than 135 professional associations of ophthalmologists worldwide and sponsors the World Opthalmology Congress (WOC). Kramer played an integral role in growing the WOC by increasing the attendance at WOC2014 in Tokyo from 13,500 to 19,000 and introducing new interactive educational delivery methods that will be implemented at the 2016 Congress.
Today AACC sent formal comments to the Centers for Medicare and Medicaid Services (CMS) addressing CMS’ proposal to enforce more stringent regulatory requirements for testing with blood glucose monitors. AACC endorses CMS’ effort to improve patient care by ensuring these devices are used appropriately, but recommends creating a transition period that would give hospitals sufficient time to adjust to the new requirements and prevent the disruption of rapid, point-of-care blood glucose results for patients.
Today AACC sent formal comments to the Food and Drug Administration (FDA) on the agency’s proposed regulation of next-generation sequencing tests. AACC appreciates FDA’s efforts to seek input from the healthcare community before developing new policy in this area, but is concerned that FDA regulation of next-generation sequencing could impede the advancement of precision medicine.
AACC and its academy, the National Academy of Clinical Biochemistry (NACB), are pleased to announce the recipients of the 2015 AACC and NACB Awards, which honor laboratory medicine professionals worldwide for advancing the field of clinical laboratory testing. Through these annual awards programs, AACC strives to support laboratory medicine practitioners in all stages of their careers and to build awareness of the essential contribution made by all laboratorians in today’s complex, changing healthcare environment.
Today AACC sent formal comments to the Food and Drug Administration (FDA) addressing FDA’s proposal for oversight of laboratory developed tests. AACC shares FDA’s goal of improving the safety and effectiveness of these crucial tests, but recommends that the agency protect patient access to the tests by limiting its oversight to high risk laboratory developed tests. AACC additionally recommends that the agency broaden its criteria exempting tests for rare diseases from its review process, and re-evaluate its proposal to require the discontinuation or FDA review of tests that fulfill unmet clinical needs once the agency clears or approves a similar commercial test.
AACC is pleased to announce that Loretta L. Doan, PhD, has assumed the position of vice president of policy and global affairs effective today. Prior to joining AACC, Doan served as director of science policy at the Endocrine Society, an organization representing more than 18,000 scientists and clinicians. At the Endocrine Society, she led a diverse portfolio of science policy initiatives that advanced the field of endocrinology, including a program focused on the standardization of hormone assays.
The U.S. House of Representatives passed a revised version of the Newborn Screening Saves Lives Reauthorization Act of 2013 yesterday, finalizing Congressional reauthorization of the legislation. AACC commends Congress for approving this bipartisan legislation, which will enable the continuation and advancement of pediatric testing programs that help thousands of infants receive life-saving treatments every year.
Today AACC released a position statement in response to the Food and Drug Administration’s (FDA’s) proposal for oversight of laboratory developed tests, asserting that most laboratory developed tests are sufficiently regulated by the Centers for Medicare and Medicaid Services, and that too much additional FDA oversight could prevent labs from helping underserved patient populations.
The U.S. Food and Drug Administration (FDA) issued its long-awaited proposal on October 3 for overseeing laboratory developed tests—medical tests that are created and used within a single lab, and often developed to fulfill unmet clinical needs. AACC is concerned that this guidance could hinder the ability of labs to provide physicians with the vital information they need to treat patients, and has joined the American Medical Association (AMA), American Hospital Association (AHA), and 48 other major healthcare organizations in requesting that FDA withdraw the draft guidance documents and re-issue them through the rulemaking process required under the Administrative Procedures Act.
Clinical laboratory testing ensures that thousands of infants receive life-saving treatments every year, yet certain pediatric testing programs could lose their funding if Congress does not finalize the Newborn Screening Saves Lives Reauthorization Act of 2013. On October 14, AACC will host a congressional briefing to discuss how this legislation could save even more children from death and disability by enabling advances in pediatric laboratory testing to continue.
AACC is pleased to announce that Patricia M. Jones, PhD, DABCC, FACB, has been elected to serve on the AACC Board as president-elect beginning in January 2015, followed by successive terms as the association’s 67th president in 2016 and past president in 2017. The AACC membership also elected two new members to the association’s Board of Directors and two new members to the Nominating Committee who will take office at the start of next year.
Now that the Ebola virus has arrived in the U.S., the ability of clinical laboratories to quickly identify patients who need treatment and require isolation will play a critical role in preventing an outbreak. To help labs prepare for this, AACC will host a webinar on October 7 featuring Nancy E. Cornish, MD, a medical officer with the Centers for Disease Control and Prevention’s Division of Laboratory Science and Standards.
On September 10, AACC will host a webinar with Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the Food and Drug Administration’s Center for Devices and Radiological Health to explain the agency’s long-awaited proposal for oversight of laboratory developed tests (LDTs). LDTs play an integral role in diagnosing a wide range of medical conditions, including congenital disorders, infectious diseases, drug abuse, and cancer.
Nearly 20,000 medical professionals and healthcare leaders gathered for AACC’s 65th Annual Meeting & Clinical Lab Expo in Chicago from July 27–31. The meeting featured never-before-seen breakthroughs in diagnostic research and technology that will advance medicine and get patients the treatment they need.
From 29 – 31 July 2014, the Swiss quality pump and valve manufacturer Diener Precision Pumps presents its precision pumps at the AACC 2014 Annual Meeting & Clinical Lab Expo in Chicago, Illinois (USA). The AACC Annual Meeting & Clinical Lab Expo is the world’s largest gathering for laboratory medicine. Double Ended – Dual Dispensing Piston Pumps and the Silencer Gear Pump Series will be the main focus of Diener Precision Pumps’ AACC appearance.
Corgenix Medical Corporation has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.
The Swiss quality manufacturer of precision pumps and valves Diener Precision Pumps increases its market presence in the USA. With its first-time participation as exhibitor at the AACC Annual Meeting & Clinical Lab Expo from 29 – 31 July 2014 in Chicago, Illinois, the company addresses specifically the US-American audience. Double Ended – Dual Dispensing Piston Pumps and the Silencer Gear Pump Series will be the focal point of Diener Precision Pumps’ AACC appearance.
One of the major revolutions taking place in healthcare is the rise of personalized medicine, which is the practice of using genomic and other molecular analyses to tailor medical treatments to a patient’s individual biology. Personalized diagnostics—laboratory analyses that inform the practice of personalized medicine—will play a major role in the lab’s future. This fall, AACC’s first ever virtual conference will feature the latest science in this exciting field and the novel technologies driving it forward, all in a convenient format that people can access without leaving their offices or homes.
As one of the 10 largest medical exhibitions in the U.S., the 2014 AACC Annual Meeting & Clinical Lab Expo is the place where breakthrough innovations in clinical testing and patient care are introduced to the healthcare world. This year, many of the trailblazing products displayed by the Expo’s 650 exhibitors will include the latest diagnostic technology in the field of mobile health.
AACC is pleased to announce the recipients of the AACC 2014 Corporate Supporter Awards. Each year, AACC recognizes the companies and organizations that generously support the association through sponsorships, advertising, and exhibiting. These significant contributions make it possible for AACC to improve patient care by fostering research, innovation, and professional excellence in the field of laboratory medicine.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right